# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k180296   
B. Purpose for Submission: Addition of a diagnostic claim to an existing device   
C. Measurand: Glycosylated Hemoglobin (HbA1c)   
D. Type of Test: Quantitative boronate affinity assay   
E. Applicant: Alere Technologies AS   
F. Proprietary and Established Names: Afinion HbA1c Dx   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Description</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation</td><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin A1cTest System</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1373</td><td rowspan=1 colspan=1>PDJ</td><td rowspan=1 colspan=1>Chemistry (75)</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indications for use below.

2. Indication(s) for use:

The Afinion HbA1c Dx is an in vitro diagnostic test for quantitative determination of glycated hemoglobin ( $\%$ hemoglobin A1c, HbA1c) in human venous and capillary whole blood. This test is to be used as an aid in the diagnosis of diabetes and as an aid in

identifying patients who may be at risk for developing diabetes. The measurement of $\%$ HbA1c is recommended as a marker of long-term metabolic control in persons with diabetes mellitus.

3. Special conditions for use statement(s):

For prescription use only.

For in vitro diagnostic use.

This device has significant negative interference with fetal hemoglobin (HbF). HbA1c results are invalid for patients with abnormal amounts of HbF including those with known Heredity Persistence of Fetal Hemoglobin.

This test should not be used to diagnose:

Diabetes during pregnancy   
Patients with an elevated fetal hemoglobin $( \mathrm { H b F } > 1 0 \%$ ) such as hereditary   
persistence of fetal hemoglobin (HPFH)   
Patients with a hemoglobinopathy but normal red cell turnover (e.g. sickle cell   
trait)   
Patients with abnormal red cell turnover (e.g. anemias from hemolysis and iron   
deficiency)   
Patients with iron deficiency and hemolytic anemia, various hemoglobinopathies,   
thalassemias, hereditary spherocytosis, malignancies, and severe chronic hepatic   
and renal disease   
Patients that have received a blood transfusion within the past 3 weeks   
Patients that have received cancer chemotherapy within the past 3 weeks

In cases of rapidly evolving type 1 diabetes the increase of HbA1c values might be delayed compared to the acute increase in glucose concentrations. In these conditions diabetes mellitus must be diagnosed based on plasma glucose concentration and/or the typical clinical symptoms.

HbA1c testing should not replace glucose testing for type 1diabetes, in pediatric patients and in pregnant women.

Coagulated or hemolyzed samples cannot be used with Afinion HbA1c Dx. Samples with $> 1 4 \%$ hemolysis $( 2 0 0 0 ~ \mathrm { m g / d L } )$ ) may return an information code.

If the sample has a hemoglobin value below $6 \mathrm { g } / \mathrm { d L }$ or above $2 0 \ \mathrm { g / d L }$ , no test result will be reported and an information code will be displayed.

4. Special instrument requirements:

Afinion AS100 analyzer

# I. Device Description:

The Afinion HbA1c Dx is a fully automated boronate affinity assay for the determination of the percentage of hemoglobin A1c in human venous and capillary whole blood. Each assay cartridge contains blue boronic acid conjugate, a tube with a polyethersulfone membrane, and washing solution (morpholine buffered sodium chloride solution with detergents and preservative). Each cartridge is labeled with a unique barcode.

The Afinion HbA1c Dx is factory calibrated and intended for use with the previously cleared Afinion AS100 Analyzer (k050574, k110056) and Afinion HbA1c Controls (k050574).

# J. Substantial Equivalence Information:

1. Predicate device name(s): Roche Diagnostics Cobas C501 Tina-Quant HbA1c cDx Gen 3 assay

2. Predicate 510(k) number(s): k121610

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Candidate DeviceAfinion HbA1c Dx</td><td colspan="1" rowspan="1">PredicateCobas c 501 Tina-QuantHbA1c Dx Gen. 3 assay(k121610)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Quantitative determinationof hemoglobin A1c for thediagnosis of diabetes and asan aid in identifying patientswho may be at risk fordeveloping diabetes</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Units of measurement</td><td colspan="1" rowspan="1">% HbA1c (DCCT/NGSP)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage requirements</td><td colspan="1" rowspan="1">2-8°C until expiration date</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">Provided by manufacturer</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">Traceable to theInternational Federation ofClinical Chemistry andLaboratory Medicine(IFCC) and DiabetesControl and ComplicationsTrial (DCCT) referencemethod. Certified via theNational Glycohemoglobin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Standardization Program(NGSP)</td><td colspan="1" rowspan="1"></td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Candidate DeviceAfinion HbA1c Dx</td><td rowspan=1 colspan=1>PredicateCobas c 501 Tina-QuantHbA1c Dx Gen. 3 assay(k121610)</td></tr><tr><td rowspan=1 colspan=1>Intended use sites</td><td rowspan=1 colspan=1>For use by health careprofessionals in clinicallaboratories and point ofcare settings</td><td rowspan=1 colspan=1>For use by health careprofessionals in clinicallaboratories</td></tr><tr><td rowspan=1 colspan=1>Assay principle</td><td rowspan=1 colspan=1>Boronate affinity assay.Hemoglobin determinationby reflectancemeasurements of blueconjugate of glycatedhemoglobin and red totalhemoglobin.</td><td rowspan=1 colspan=1>HbA1c determination byturbidimetric inhibitionimmunoassay method.Hemoglobin determinationby converting to aderivative with acharacteristic absorptionspectrum which ismeasured bichromatically.</td></tr><tr><td rowspan=1 colspan=1>Sample types</td><td rowspan=1 colspan=1>Anticoagulated venouswhole blood (K2-EDTA),and capillary whole blood(fingerstick)</td><td rowspan=1 colspan=1>Anticoagulated venouswhole blood (K2-EDTA,K3-EDTA, Li-Heparin, Na-Heparin, NaF/Na2-EDTA,NaF/K-oxalate, KF/ Na2-EDTA)</td></tr><tr><td rowspan=1 colspan=1>Analyzer</td><td rowspan=1 colspan=1>Alere Afinion AS100</td><td rowspan=1 colspan=1>Cobas c 501</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Factory calibrated, no usercalibration required</td><td rowspan=1 colspan=1>User calibration usingcalibrators provided bymanufacturer</td></tr><tr><td rowspan=1 colspan=1>Assay range</td><td rowspan=1 colspan=1>4.00 - 15.00 % HbA1c</td><td rowspan=1 colspan=1>4.2 - 20.1 % HbA1c</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Clinical and Laboratory Standards Institute (CLSI) EP5-A3 Evaluation of Precision Performance of Quantitative Measurement Methods, Approved Guideline—Third Edition.

CLSI EP7-A2 Interference Testing in Clinical Chemistry, Approved Guideline –- Second Edition

# CLSI EP5-A3 Evaluation of Precision of Quantitative Measurement Procedures- Approved Guideline –Third Edition

ISO 14971 Second edition 2007-03-01, Medical devices - application of risk management to medical devices

EN ISO 14971:2012 Medical devices, Application of risk management to medical devices

# L. Test Principle:

A blood sample is collected with the integrated sampling device, which is then inserted into the Alere HbA1c Dx test cartridge. The cartridge/sampling device combination is then placed into the cartridge chamber of the Alere Afinion AS100 Analyzer. The sample is automatically diluted and mixed with a solution that releases hemoglobin from the erythrocytes. After the hemoglobin is precipitated, the sample mixture is transferred to a blue boronic acid conjugate which binds to the cis-diols of glycated hemoglobin. This reaction mixture is soaked through a filter membrane and all precipitated hemoglobin, conjugatebound and unbound (i.e. glycated and nonglycated hemoglobin) remains on the membrane. Excess conjugate is removed with a washing reagent. The analyzer measures the reflectance of the precipitate on the membrane as blue (glycated hemoglobin) and red (total hemoglobin) color intensities. The analyzer calculates a ratio proportional to the percentage of HbA1c in the sample and displays as the $\%$ HbA1c (DCCT/NGSP).

# M.Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Internal precision study using venous whole blood

An internal precision study was performed according to CLSI guideline EP05-A3. Four $\mathrm { K } _ { 2 }$ -EDTA venous whole blood samples at concentrations near $5 \%$ , $6 . 5 \%$ , $8 \%$ and $12 \%$ HbA1c were analyzed by eleven operators in duplicate, twice a day, with three lots of reagents, over 20 days each, on nine Afinion AS100 analyzers (three lots per analyzer, three analyzers per sample). For each sample, there were 720 measurements. Results are shown in the tables below:

Analyzer 1 $( \mathtt { n } = 2 4 0 )$ :   

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=2 colspan=1>Mean%HbA1c</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between run</td><td rowspan=1 colspan=2>Between day</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.13</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.037</td><td rowspan=1 colspan=1>0.72</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>1.63</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.53</td><td rowspan=1 colspan=1>0.086</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.114</td><td rowspan=1 colspan=1>1.74</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.09</td><td rowspan=1 colspan=1>0.082</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.095</td><td rowspan=1 colspan=1>1.17</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>11.33</td><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>0.105</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>0.149</td><td rowspan=1 colspan=1>1.32</td></tr></table>

Analyzer 2 $( \mathtt { n } = 2 4 0 )$ :   

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between run</td><td rowspan=1 colspan=2>Between day</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>%HbA1c</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.11</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>0.046</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>1.63</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.53</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>1.07</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>0.67</td><td rowspan=1 colspan=1>0.064</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.106</td><td rowspan=1 colspan=1>1.62</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.01</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>1.04</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>11.17</td><td rowspan=1 colspan=1>0.086</td><td rowspan=1 colspan=1>0.77</td><td rowspan=1 colspan=1>0.015</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>0.54</td><td rowspan=1 colspan=1>0.094</td><td rowspan=1 colspan=1>0.84</td><td rowspan=1 colspan=1>0.142</td><td rowspan=1 colspan=1>1.27</td></tr></table>

Analyzer 3 $( \mathtt { n } = 2 4 0 )$ :   

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between run</td><td rowspan=1 colspan=2>Between day</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>%HbA1c</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.18</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.074</td><td rowspan=1 colspan=1>1.43</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.58</td><td rowspan=1 colspan=1>0.066</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>1.27</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.08</td><td rowspan=1 colspan=1>0.086</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.116</td><td rowspan=1 colspan=1>1.43</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>11.30</td><td rowspan=1 colspan=1>0.114</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.098</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.155</td><td rowspan=1 colspan=1>1.37</td></tr></table>

All analyzers combined $( \mathtt { n } = 7 2 0 )$ :   

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between run Between day</td><td rowspan=1 colspan=2>Between run Between day</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Betweenanalyzer</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>%HbA1</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.14</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.041</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>1.64</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.55</td><td rowspan=1 colspan=1>0.074</td><td rowspan=1 colspan=1>1.13</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>0.056</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>1.51</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.06</td><td rowspan=1 colspan=1>0.077</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.31</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>11.26</td><td rowspan=1 colspan=1>0.101</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>0.099</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>0.059</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>1.42</td></tr></table>

# External precision study using venous whole blood

An external precision study was performed at three point-of-care moderate complexity laboratory sites in the US. Four $\mathrm { K } _ { 2 }$ -EDTA venous whole blood samples at concentrations near $5 \%$ , $6 . 5 \%$ , $8 \%$ and $12 \%$ HbA1c were analyzed by two to three operators per site using six Afinion AS100 analyzers and three lots of reagent. Four replicates were analyzed twice a day for 10 days for a total of 240 measurements per sample at each site. The data was analyzed according to CLSI EP05-A3 and results are shown in the table below:

All sites combined:   

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between run</td><td rowspan=1 colspan=2>Between day</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Betweenanalyzer</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>%HbA1</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>5.02</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>1.21</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>0.046</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>0.085</td><td rowspan=1 colspan=1>1.78</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>6.41</td><td rowspan=1 colspan=1>0.071</td><td rowspan=1 colspan=1>1.11</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>0.74</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.095</td><td rowspan=1 colspan=1>1.48</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>8.18</td><td rowspan=1 colspan=1>0.090</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>0.51</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>0.104</td><td rowspan=1 colspan=1>1.36</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>12.09</td><td rowspan=1 colspan=1>0.118</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>0.046</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.059</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>0.134</td><td rowspan=1 colspan=1>1.22</td></tr></table>

# Capillary blood (fingerstick) precision:

Capillary blood (fingerstick) precision estimates are based on a combination of three separate studies as described below:

i. Capillary blood (fingerstick) precision estimates for repeatability and between-lot were calculated from measurements obtained during the method comparison study. Ten intended use operators analyzed duplicate fingerstick samples from 170 subjects with three reagent lots in total (two lots per site) on five Afinion AS100 analyzers at three sites. The samples were grouped into four %HbA1c concentration intervals (4.00-5.99, 6.00-6.99, 7.00-9.99, 10.00- 15.00) and analyzed according to CLSI guideline EP05-A3. Results are presented in the table below:

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Minimum%HbA1c</td><td rowspan=2 colspan=1>Maximum%HbA1c</td><td rowspan=2 colspan=1>Average%HbA1c</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between lot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>4.77</td><td rowspan=1 colspan=1>5.99</td><td rowspan=1 colspan=1>5.42</td><td rowspan=1 colspan=1>0.082</td><td rowspan=1 colspan=1>1.52</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>0.105</td><td rowspan=1 colspan=1>1.93</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>6.00</td><td rowspan=1 colspan=1>6.98</td><td rowspan=1 colspan=1>6.46</td><td rowspan=1 colspan=1>0.088</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>0.092</td><td rowspan=1 colspan=1>1.42</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>7.02</td><td rowspan=1 colspan=1>9.94</td><td rowspan=1 colspan=1>7.93</td><td rowspan=1 colspan=1>0.107</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.107</td><td rowspan=1 colspan=1>1.35</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>10.07</td><td rowspan=1 colspan=1>11.52</td><td rowspan=1 colspan=1>10.72</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>0.62</td></tr></table>

ii. To capture repeatability, between-instrument, and between-operator precision estimates, an external study was performed at three point-of-care moderate complexity laboratory sites in the US. Samples in four $\% _ { \mathrm { \tiny \mathrm { ~ H b A l { c } } } }$ concentration intervals (4.00-5.99, 6.00-6.99, 7.00-9.99, 10.00-15.00) from five or six subjects per interval were analyzed by three operators per site using two Afinion AS100 analyzers. Six fingerstick samples (two fingerstick samples from each subject were collected and measured per operator) were analyzed for a total of 30 or 36 measurements (M) per sample level at each site $( \mathrm { n } { = } 9 0$ or $\scriptstyle \mathrm { n = 9 6 }$ measurements across sites). The results from all sites combined are shown in the table below.

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=2 colspan=1>N (M)</td><td rowspan=2 colspan=1>Average%HbA1c</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>BetweenOperator</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>15 (90)</td><td rowspan=1 colspan=1>5.33</td><td rowspan=1 colspan=1>0.074</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>0.008</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>1.40</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>15 (90)</td><td rowspan=1 colspan=1>6.51</td><td rowspan=1 colspan=1>0.081</td><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>1.28</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>16 (96)</td><td rowspan=1 colspan=1>8.32</td><td rowspan=1 colspan=1>0.092</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>0.093</td><td rowspan=1 colspan=1>1.12</td></tr><tr><td rowspan=1 colspan=1>High</td><td rowspan=1 colspan=1>15 (90)</td><td rowspan=1 colspan=1>12.20</td><td rowspan=1 colspan=1>0.139</td><td rowspan=1 colspan=1>1.14</td><td rowspan=1 colspan=1>0.057</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.150</td><td rowspan=1 colspan=1>1.23</td></tr></table>

iii. Between-Run and Between-Day precision estimates for capillary blood were transferred from the internal venous whole blood precision study described above.

The combined precision estimates $( \% C V )$ from the three studies are shown in the table below.

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=2>Fingerstick AccuracyPrecision</td><td rowspan=1 colspan=2>Internal VenousPrecision Study</td><td rowspan=1 colspan=3>Fingerstick Precision Study</td><td rowspan=2 colspan=1>Total%CV</td></tr><tr><td rowspan=1 colspan=1>Repeatability</td><td rowspan=1 colspan=1>BetweenLot</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Repeatability</td><td rowspan=1 colspan=1>BetweenInstrument</td><td rowspan=1 colspan=1>BetweenOperator</td></tr><tr><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>1.52</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>2.03</td></tr><tr><td rowspan=1 colspan=1>Threshold</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>0.42</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.62</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.58</td></tr><tr><td rowspan=1 colspan=1>Medium</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>1.49</td></tr><tr><td rowspan=1 colspan=1>*High</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>1.14</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1.30</td></tr></table>

\*This estimate of the Total $\% \mathrm { C V }$ for High HbA1c $( \geq 1 0 \% )$ is based on the within run component of variance estimated in the Fingerstick Precision Study since the precision study has a larger sample size than the Fingerstick Accuracy Precision Study.

b. Linearity/assay reportable range:

Linearity was previously established for the range of $4 . 0 0 - 1 5 . 0 0 \%$ HbA1c (DCCT/NGSP) in k050574.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The Afinion HbA1c Dx assay is certified with the National Glycohemoglobin Standardization Program (NGSP). The NGSP certification expires in one year. See NGSP website for current certification at http://www.ngsp.org. Traceability is verified annually through the IFCC Whole Blood Monitoring Program.

Test results are calculated in mmol/mol (IFCC). HbA1c values are further reported according to the National Glycohemoglobin Standardization Program (NGSP) recommendations at DCCT (Diabetes Control and Complications Trial) level. The IFCC Master Equation for the relationship between the IFCC-Reference Method (RM) and the NGSP-Designated Comparison Method (DCM) is used for conversion of the test results:

NGSP-HbA1c $( \% ) =$ DCCT-HbA1c $( \% ) = 0 . 0 9 1 4 8 \mathrm { ~ x ~ }$ IFCC-HbA1c $\mathrm { ( m m o l / m o l ) + }$ 2.152

d. Detection limit:

The Limit of Quantification was previously established as $4 . 0 \%$ HbA1c in k050574.

e. Analytical specificity:

i. Exogenous and endogenous interference

Interference from 20 drug substances and six endogenous compounds was evaluated using $\mathrm { K } _ { 2 }$ -EDTA venous whole blood samples with low $( \sim 6 . 5 \% )$ and high $( \geq 8 . 5 \% )$ HbA1c levels. Test samples were prepared by spiking each drug or endogenous substance into the low and high samples and comparing to control samples containing no drug. The test and control samples were tested in 10 replicates using two lots of reagent. The sponsor defined significant interference as greater than or equal to $7 \%$ difference from the expected concentration. Results demonstrated that no significant interference was observed with the following substances up to the listed concentrations:

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Highest concentration testedwith no significantinterference</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Acetylcysteine</td><td rowspan=1 colspan=1>166 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>30 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin -conjugated</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin - unconjugated</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>250 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine A</td><td rowspan=1 colspan=1>0.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine C</td><td rowspan=1 colspan=1>0.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Doxycyclin</td><td rowspan=1 colspan=1>5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Glyburide</td><td rowspan=1 colspan=1>0.20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>5000 U/L</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Levodopa</td><td rowspan=1 colspan=1>2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Metformin</td><td rowspan=1 colspan=1>4 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Methyldopa</td><td rowspan=1 colspan=1>2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid factor</td><td rowspan=1 colspan=1>780 000 IU/L</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>6.4 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Salicylic acid</td><td rowspan=1 colspan=1>59 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>10 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Total protein (human serumalbumin added and native total</td><td rowspan=1 colspan=1>150 g/L</td></tr></table>

Potential interference from hemolysis was evaluated using two $\mathrm { K } _ { 2 }$ -EDTA venous whole blood samples at $6 . 5 \%$ and ${ \sim } 9 . 5 \%$ HbA1c. Test samples were spiked with hemolysates generated by a freeze/thaw cycle of native samples and compared to control samples containing no hemolysate. The sponsor defined significant interference as greater than or equal to $7 \%$ difference from the expected

concentration. The results support the sponsor’s claim that hemolysis up to $1 3 . 8 \%$ does not interfere with their device. The labeling states that “hemolyzed samples with $> 1 4 \%$ hemolysis $2 0 0 0 \mathrm { m g / d L } )$ may return an information code.”.

# ii. Cross reactivity with Hemoglobin Derivatives

Potential cross reactivity with acetylated hemoglobin, carbamylated hemoglobin, labile HbA1c, and glycated albumin was evaluated. Two $\mathrm { K } _ { 2 }$ -EDTA venous whole blood samples at $6 . 5 \%$ and ${ \sim } 8 . 5 \%$ HbA1c were spiked with the potential interferent ${ ( 6 . 0 \mathrm { m g / m L } }$ acetylated hemoglobin, $1 4 . 1 \mathrm { m g / m L }$ carbamylated hemoglobin, $1 2 . 4 ~ \mathrm { m g / m L }$ labile HbA1c, $7 . 7 \ : \mathrm { m g / m L }$ glycated albumin). Ten replicates of test and control samples were analyzed. The sponsor defined significant interference as greater than or equal to $7 \%$ difference from the expected concentration. The testing results support the sponsor’s claim in the labeling that there is no cross reactivity with acetylated hemoglobin $( 4 . 6 \mathrm { m g / m L } )$ , carbamylated hemoglobin ( $1 3 . 8 ~ \mathrm { m g / m L }$ ), labile HbA1c ( $1 1 . 4 \mathrm { m g / m L }$ , or glycated albumin $( 7 . 7 \mathrm { m g / m L } )$ ).

Potential cross reactivity from HbA0, HbA1a and HbA1b was evaluated using 100 samples. Two HbA1c concentrations of pooled $\mathrm { K } _ { 2 }$ -EDTA venous whole blood samples at $6 . 0 \%$ and $9 . 0 \%$ HbA1c (range $4 . 3 \%$ to $1 3 . 9 3 \%$ HbA1c) containing HbA0 ( $82 \%$ to $9 5 \%$ ), HbA1a ( $0 . 4 \%$ to $1 . 4 \%$ ) and HbA1b ( $0 . 4 \%$ to $2 . 3 \%$ were tested in singlicate using an Afinion AS100 analyzer and compared to measurements made using a NGSP comparator method (Tosoh G8 HPLC). The sponsor defined significant interference as greater than or equal to $7 \%$ difference from the expected concentration. The testing results support the sponsor’s claim in the labeling that there is no cross reactivity with HbA0 (up to $9 5 \%$ ), HbA1a (up to $1 . 4 \%$ ), and HbA1b (up to $2 . 3 \%$ ).

# iii) Hemoglobin Variant Interference

For the hemoglobin variant interference study was performed using a total of 221 $\mathrm { K } _ { 2 }$ -EDTA venous whole blood samples known to contain common hemoglobin variants (HbA2, HbS, HbC, HbE, HbD, and HbF). Results obtained by a FDA cleared method that has been demonstrated to be free from the hemoglobin interference being tested (Premier Hb9210 for HbA2, HbAS, HbE, and Tosoh Automated Glycohemoglobin Analyzer HLC-723 G8 for HbF). The sponsor’s definition of non-significant interference is $\leq 7 \%$ mean relative deviation between the Afinion HbA1c Dx result and the NGSP comparator method.

Samples used for interference evaluation:   

<table><tr><td colspan="1" rowspan="1">HemoglobinVariant</td><td colspan="1" rowspan="1">Number ofSamplesTested</td><td colspan="1" rowspan="1">% Content ofVariant insample</td><td colspan="1" rowspan="1">Range inConcentration in% HbA1c</td></tr><tr><td colspan="1" rowspan="1">HbA2</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">3.9-5.7</td><td colspan="1" rowspan="1">5.8-10.6</td></tr><tr><td colspan="1" rowspan="1">HbS</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">35-42</td><td colspan="1" rowspan="1">5.6-8.8</td></tr><tr><td colspan="1" rowspan="1">HbC</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">30-36</td><td colspan="1" rowspan="1">5.5-9.7</td></tr><tr><td colspan="1" rowspan="1">HbE</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">17-26</td><td colspan="1" rowspan="1">6.1-8.9</td></tr><tr><td colspan="1" rowspan="1">HbD</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">27-42</td><td colspan="1" rowspan="1">6.1-9.4</td></tr><tr><td colspan="1" rowspan="1">HbF</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">3.4-28.1</td><td colspan="1" rowspan="1">5.0-11.3</td></tr></table>

Hemoglobin Variant Result Summary:   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Mean % Bias (range of relative bias) fromComparator Method</td></tr><tr><td rowspan=1 colspan=1>Hb Variant</td><td rowspan=1 colspan=1>~6.5 %HbA1c</td><td rowspan=1 colspan=1>~8.5 % HbA1c</td></tr><tr><td rowspan=1 colspan=1>HbA2</td><td rowspan=1 colspan=1>-3.4 % (-6.2% to -1.4%)</td><td rowspan=1 colspan=1>-2.5 % (-6.6% to 2.8%)</td></tr><tr><td rowspan=1 colspan=1>HbS</td><td rowspan=1 colspan=1>-4.1 % (-6.6% to 3.2%)</td><td rowspan=1 colspan=1>-1.0 % (-9.9% to 3.5%)</td></tr><tr><td rowspan=1 colspan=1>HbC</td><td rowspan=1 colspan=1>-5.5 % (-8.5% to -1.8%)</td><td rowspan=1 colspan=1>-1.8 % (-5.2% to 1.1%)</td></tr><tr><td rowspan=1 colspan=1>HbE</td><td rowspan=1 colspan=1>3.5 % (1.4% to 7.9%)</td><td rowspan=1 colspan=1>3.7 % (0% to 4.7)</td></tr><tr><td rowspan=1 colspan=1>HbD</td><td rowspan=1 colspan=1>-2.2 % (-4.1% to 0%)</td><td rowspan=1 colspan=1>-2.9 % (-5.9% to 0%)</td></tr><tr><td rowspan=1 colspan=1>HbF</td><td rowspan=1 colspan=2>10.4% HbF is the highest HbF concentration where nosignificant interference is observed with significantinterference defined as &gt; ±7%.</td></tr></table>

The testing results show there is no significant interference for Hemoglobin A2 $( \geq$ $5 . 7 \%$ , Hemoglobin S $( \geq 4 2 \% )$ , Hemoglobin C $( \geq 3 6 \% )$ , Hemoglobin E $( \geq 2 6 \% )$ , and Hemoglobin D $( \geq 4 2 \% )$ .

The package insert labeling states:

No significant interference for Hemoglobin A2, Hemoglobin C, Hemoglobin D, Hemoglobin E, and Hemoglobin S up to the levels stated.

The results show that there is significant interference due to the presence of HbF at a HbF concentration of $> 1 0 . 4 \%$ . The device labeling contains the following prominent boxed warning:

“This device has significant negative interference with fetal hemoglobin (HbF). HbA1c results are invalid for patients with abnormal amounts of HbF including those with known Heredity Persistence of Fetal Hemoglobin. Refer to the Analytical specificity and Limitations sections in this package insert for details.”

f. Assay cut-off: Not applicable.

2. Comparison studies:

# a. Method comparison with predicate device:

A method comparison study was conducted using 120 capillary (fingerstick) whole blood samples and matched $\mathrm { K } _ { 2 }$ -EDTA venous whole blood samples ranging from 4.6 to $1 1 . 4 \%$ HbA1c. All samples were tested with two Afinion HbA1c Dx reagent lots at three moderate complexity point-of-care laboratories. The distribution of samples spanned a concentration around the clinical decision points as follows:

<table><tr><td rowspan=1 colspan=1>Hemoglobin A1c level</td><td rowspan=1 colspan=1>Number of samples</td><td rowspan=1 colspan=1>Percent of samples</td></tr><tr><td rowspan=1 colspan=1>4-5%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>4.2%</td></tr><tr><td rowspan=1 colspan=1>5.1 - 6%</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>12.5%</td></tr><tr><td rowspan=1 colspan=1>6.1 - 6.5%</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>25.0%</td></tr><tr><td rowspan=1 colspan=1>6.6 - 7%</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>25.0%</td></tr><tr><td rowspan=1 colspan=1>7.1 - 8%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>16.7%</td></tr><tr><td rowspan=1 colspan=1>8.1 - 9%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.3%</td></tr><tr><td rowspan=1 colspan=1>9.1 - 15%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>8.3%</td></tr><tr><td rowspan=1 colspan=1>Total samples</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>100%</td></tr></table>

Singlicate capillary and venous whole blood results from the Afinion HbA1c Dx test system were compared to average results from matched $\mathrm { K } _ { 2 }$ -EDTA venous whole blood samples tested in duplicate using a NGSP comparator method (Tosoh G8 HPLC).

Deming (weighted) and Passing-Bablok regression analyses were performed for the Afinion HbA1c Dx assay versus the comparator method.

Fingerstick capillary whole blood samples

Weighted Deming regression:   

<table><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.997</td><td rowspan=1 colspan=1>0.966 - 1.027 (slope)-0.209 - 0.201 (intercept)</td></tr></table>

![](images/4ee0c6c9316851ce4fdd3bf9153257ae5b64fad15fa98a33753514d6bf429704.jpg)

Passing-Bablok regression:   

<table><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>-0.040</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>0.971- 1.033 (slope)-0.271 - 0.165 (intercept)</td></tr></table>

![](images/062cac1c1bbed4026bdac328fcc44143c3f5f91ac97776784e061aebc03e203d.jpg)

The following biases for fingerstick blood samples were observed between the Afinion HbA1c Dx and the comparator method:

<table><tr><td rowspan=2 colspan=1>Decision Level</td><td rowspan=1 colspan=2>Weighted Deming regression</td><td rowspan=1 colspan=2>Passing-Bablok regression</td></tr><tr><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>% Bias</td></tr><tr><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>-0.017</td><td rowspan=1 colspan=1>-0.335</td><td rowspan=1 colspan=1>-0.040</td><td rowspan=1 colspan=1>-0.800</td></tr><tr><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>-0.022</td><td rowspan=1 colspan=1>-0.334</td><td rowspan=1 colspan=1>-0.040</td><td rowspan=1 colspan=1>-0.615</td></tr><tr><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>-0.027</td><td rowspan=1 colspan=1>-0.334</td><td rowspan=1 colspan=1>-0.040</td><td rowspan=1 colspan=1>-0.500</td></tr><tr><td rowspan=1 colspan=1>12.0%</td><td rowspan=1 colspan=1>-0.040</td><td rowspan=1 colspan=1>-0.333</td><td rowspan=1 colspan=1>-0.040</td><td rowspan=1 colspan=1>-0.333</td></tr></table>

Venous whole blood samples

Weighted Deming regression:

<table><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>0.991</td><td rowspan=1 colspan=1>0.959- 1.022 (slope)-0.162  0.270 (intercept)</td></tr></table>

![](images/cd57e3d7e6a82396eaec784ce29a9b9ccb5afd81169ce33acfd92f28c75015a3.jpg)

Passing-Bablok regression:   

<table><tr><td rowspan=1 colspan=1>y-intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>-0.030</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>0.968 - 1.031 (slope)-0.232  0.184 (intercept)</td></tr></table>

![](images/4800250a6ac41660ad28d69f103f3b4e069b7b58473701ff1606288c737ce1a6.jpg)

The following biases were observed between the Afinion HbA1c Dx and the comparator method:

<table><tr><td rowspan=2 colspan=1>Decision Level</td><td rowspan=1 colspan=2>Weighted Deming regression</td><td rowspan=1 colspan=2>Passing-Bablok regression</td></tr><tr><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>% Bias</td></tr><tr><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>0.195</td><td rowspan=1 colspan=1>-0.030</td><td rowspan=1 colspan=1>-0.600</td></tr><tr><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>-0.003</td><td rowspan=1 colspan=1>-0.052</td><td rowspan=1 colspan=1>-0.030</td><td rowspan=1 colspan=1>-0.462</td></tr><tr><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>-0.017</td><td rowspan=1 colspan=1>-0.206</td><td rowspan=1 colspan=1>-0.030</td><td rowspan=1 colspan=1>-0.375</td></tr><tr><td rowspan=1 colspan=1>12.0%</td><td rowspan=1 colspan=1>-0.051</td><td rowspan=1 colspan=1>-0.429</td><td rowspan=1 colspan=1>-0.030</td><td rowspan=1 colspan=1>-0.250</td></tr></table>

# Total Error Calculations

Using the results of bias estimation ( $\%$ Bias) in the method comparison study and precision estimates, Total Error (TE) at four concentrations $( 5 . 0 \%$ , $6 . 5 \%$ , $8 . 0 \%$ , and $1 2 . 0 \% )$ was calculated using all components of variance as stated in the special controls as follows: $\begin{array} { r } { \% \ { } \operatorname { T E } = \mathrm { | \% \ B i a s | } + 1 . 9 6 \ { } ^ { * 0 } / \mathrm { { o } \ C V ^ { * } ( 1 + \% \ B i a s / } } \end{array}$ 100). The results are presented in the tables below.

Capillary fingerstick samples:

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=2 colspan=1>%CV</td><td rowspan=1 colspan=2>Weighted Deming regression</td><td rowspan=1 colspan=2>Passing-Bablok regression</td></tr><tr><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%TE</td><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>2.03</td><td rowspan=1 colspan=1>-0.335</td><td rowspan=1 colspan=1>4.30</td><td rowspan=1 colspan=1>-0.800</td><td rowspan=1 colspan=1>4.75</td></tr><tr><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>1.58</td><td rowspan=1 colspan=1>-0.334</td><td rowspan=1 colspan=1>3.42</td><td rowspan=1 colspan=1>-0.615</td><td rowspan=1 colspan=1>3.69</td></tr><tr><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>1.49</td><td rowspan=1 colspan=1>-0.334</td><td rowspan=1 colspan=1>3.24</td><td rowspan=1 colspan=1>-0.500</td><td rowspan=1 colspan=1>3.40</td></tr><tr><td rowspan=1 colspan=1>12.0%</td><td rowspan=1 colspan=1>1.30</td><td rowspan=1 colspan=1>-0.333</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>-0.333</td><td rowspan=1 colspan=1>2.87</td></tr></table>

EDTA venous whole blood samples (based on external point-of-care precision study):

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=2 colspan=1>%CV</td><td rowspan=1 colspan=2>Weighted Deming regression</td><td rowspan=1 colspan=2>Passing-Bablok regression</td></tr><tr><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%TE</td><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>1.78</td><td rowspan=1 colspan=1>0.195</td><td rowspan=1 colspan=1>3.69</td><td rowspan=1 colspan=1>-0.600</td><td rowspan=1 colspan=1>4.07</td></tr><tr><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>1.48</td><td rowspan=1 colspan=1>-0.052</td><td rowspan=1 colspan=1>2.95</td><td rowspan=1 colspan=1>-0.462</td><td rowspan=1 colspan=1>3.35</td></tr><tr><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>-0.206</td><td rowspan=1 colspan=1>2.87</td><td rowspan=1 colspan=1>-0.375</td><td rowspan=1 colspan=1>3.03</td></tr><tr><td rowspan=1 colspan=1>12.0%</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>-0.429</td><td rowspan=1 colspan=1>2.81</td><td rowspan=1 colspan=1>-0.250</td><td rowspan=1 colspan=1>2.64</td></tr></table>

EDTA venous whole blood samples (based on internal precision study):

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=2 colspan=1>%CV</td><td rowspan=1 colspan=2>Weighted Deming regression</td><td rowspan=1 colspan=2>Passing-Bablok regression</td></tr><tr><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%TE</td><td rowspan=1 colspan=1>%Bias</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>1.64</td><td rowspan=1 colspan=1>0.195</td><td rowspan=1 colspan=1>3.42</td><td rowspan=1 colspan=1>-0.600</td><td rowspan=1 colspan=1>3.80</td></tr><tr><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>1.51</td><td rowspan=1 colspan=1>-0.052</td><td rowspan=1 colspan=1>3.01</td><td rowspan=1 colspan=1>-0.462</td><td rowspan=1 colspan=1>3.41</td></tr><tr><td rowspan=1 colspan=1>8.0%</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>-0.206</td><td rowspan=1 colspan=1>2.77</td><td rowspan=1 colspan=1>-0.375</td><td rowspan=1 colspan=1>2.93</td></tr><tr><td rowspan=1 colspan=1>12.0%</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>-0.429</td><td rowspan=1 colspan=1>3.20</td><td rowspan=1 colspan=1>-0.250</td><td rowspan=1 colspan=1>3.03</td></tr></table>

$b$ . Matrix comparison:

Not applicable. Venous $\mathrm { K } _ { 2 }$ -EDTA and capillary are the only matrices claimed for this assay.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
$b$ . Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable.

4. Clinical cut-off: See expected values, below.

5. Expected values/Reference range:

The diagnostic cut-off is $6 . 5 \%$ HbA1c. Patients with HbA1c values in the range 5.7-6.4 $\%$ are identified as having an increased risk for developing diabetes1,2.

1International Expert Committee, International Expert Committee Report on the Role of the A1c Assay in the Diagnosis of Diabetes. Diabetes Care 2009; 32(7):1237-1334.

2American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care   
2018; 41(Suppl. 1): S13-S27.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.